For LUAD, the most common type of NSCLC, drugs that target specific mutated drivers such as EGFR,3 ALK,4 and KRAS5 have been developed and display remarkable therapeutic effects. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.